The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Neurol.
Sec. Neuromuscular Disorders and Peripheral Neuropathies
Volume 16 - 2025 |
doi: 10.3389/fneur.2025.1537783
Autoantibodies in Myasthenia Gravis: Cluster Analysis, and Clinical Correlations
Provisionally accepted- 1 Department of Neurology, Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China
- 2 Jinan Dian Medical Laboratory CO., LTD. Shandong, China, qingdao, China
- 3 Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Provinces, Hangzhou, Jiangsu Province, China
Objective: This study aims to explore autoantibody clusters and their correlations with clinical features in 644 myasthenia gravis (MG) patients.Methods: Medical records of 664 MG patients were reviewed. Five autoantibodies (AChR, MuSK, titin, RyR and LRP4) were selected for cluster analysis. The various clinical manifestations were compared between clusters. Separate association analyses between individual autoantibodies and clinical manifestations as well as among different MGFA subtypes were also performed without prior clustering.Results: Two separate autoantibody clusters were identified, with significantly different clinical manifestations. Cluster 1 (485 patients) was characterized by higher proportions of RyR-, titin-, and AChR-, while cluster 2 (179 patients) had higher proportions of RyR+, titin+, and AChR+. Cluster 2 patients were older and had elevated QMG scores and odds of complications, particularly hypertension, diabetes, cardiovascular and cerebrovascular diseases, and eye conditions. Individual antibody analysis revealed male cases were more likely to be AChR+ and titin+, and older age was associated with AChR+, RyR+ and titin+. Among MGFA subtypes, significant differences were detected in AChR, MuSk, titin, complications, thymoma, and hypertension. As MG severity increased from type I to type V, AChR+, RyR+, and titin+ proportions peaked at stage IIa. MuSK+ patients were relatively rare and mostly present in the subtype b group. Type b patients had higher MuSk+ prevalence and increased cardiovascular and cerebrovascular disease incidence rates compared with type a cases.Overall, cluster 2 features were less favorable to patients. This study provides valuable insights into the clinical and autoantibody profiles of Chinese MG patients.
Keywords: Myasthenia Gravis, Antibodies, clinical manifestations, Cluster analysis, clinical research
Received: 01 Dec 2024; Accepted: 16 Jan 2025.
Copyright: © 2025 Sun, Qu, Rong, Lv, Zhao, Yan, liu, Sun, Yue and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Meijie Qu, Department of Neurology, Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China
Xi Rong, Department of Neurology, Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China
Mingxing Lv, Department of Neurology, Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China
Yunbin Zhao, Department of Neurology, Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China
lin liu, Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Provinces, Hangzhou, 310030, Jiangsu Province, China
Na Sun, Jinan Dian Medical Laboratory CO., LTD. Shandong, China, qingdao, China
Hua Yue, Department of Neurology, Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China
Min Liu, Department of Neurology, Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.